Caprock Group’s Medifast MED Stock Holding History

Caprock Group’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,000	Closed	-$213K	–	544
2021 Q1	$213K	Buy	+1,000	New	+$239K	0.02%	443

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Caprock Group's MED Position: Q2 2021 in Review

Caprock Group sold out of Medifast (MED) in Q2 2021, closing a stake of 1,000 shares — an estimated $213K sold.

Caprock Group first reported a position in MED in Q1 2021 and held it in 1 quarter. The position peaked at $213K in Q1 2021. 301 funds tracked by Wall St. Rank hold MED as of Q2 2021.

Caprock Group reported no remaining Medifast position as of Q2 2021 after selling out during the quarter.
Caprock Group sold 1,000 Medifast shares in Q2 2021, an estimated $213K.
Caprock Group first reported a position in Medifast in Q1 2021 and held it in 1 quarter.
Caprock Group's Medifast position peaked at $213K in Q1 2021.
301 funds tracked by Wall St. Rank held Medifast as of Q2 2021.

Based on Caprock Group's 13F filing for Q2 2021, filed 13 Aug 2021.